<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01809717</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 13412</org_study_id>
    <nct_id>NCT01809717</nct_id>
  </id_info>
  <brief_title>Multiple Myeloma and Exercise</brief_title>
  <official_title>Modulating The Toxicity And Efficacy Of High Dose Chemotherapy For Multiple Myeloma Through An Intervention To Increase Lean Body Mass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will establich the feasibility of weight lifting exercise among patients with&#xD;
      multiple myeloma, determine if weight lifting exercise increases lean body mass among&#xD;
      patients with multiple myeloma and obtain further preliminary data on toxicity and&#xD;
      pharmacokinetics of high-dose melphalan.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single-institution, pilot study of a 3 month weight lifting program&#xD;
      designed to increase musle hypertrophy prior to starting stem cell collection and receiving&#xD;
      high-dose melphalan, in patients with multiple myeloma. We will use this exercise&#xD;
      intervention while patients are receiving initial induction chemotherapy in the 3-6 month&#xD;
      period before they receiv high-dose melphalan. The primary study endpoint is to determine the&#xD;
      feasibility of recruiting and retaining multiple myeloma patients to an exercise intervention&#xD;
      trial. The secondary study endpoint is to determine whether the weight lifting program&#xD;
      increases lean body mass as intended.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>3-6 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Newly Diagnosed Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Weight Lifting Exercises</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Weight Lifting Exercises</intervention_name>
    <arm_group_label>Weight Lifting Exercises</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed multiple myeloma&#xD;
&#xD;
          -  1 year since start of treatment for myeloma&#xD;
&#xD;
          -  Patient and treating physician in agreement to proceed with autologous transplant,&#xD;
             with a planned time betwwen study enrollment and transplant of 10 weeks&#xD;
&#xD;
          -  Age 18 years.&#xD;
&#xD;
          -  Able to walk for 6 minutes unaided.&#xD;
&#xD;
          -  Body mass index 50 kg/m2&#xD;
&#xD;
          -  Serum creatinine 2.5 mg/dL&#xD;
&#xD;
          -  Ability to understand the informed consent document and willingness to consent.&#xD;
             Written informed consent must be obtained from all patients before study entry.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Recent (in the past 6 months) participation in progressive weight lifting exercises or&#xD;
             who already exercise regulary (3 times a week of moderate intensity aerobic exercise).&#xD;
&#xD;
          -  Plan to move out of the area during the study intervention.&#xD;
&#xD;
          -  A psychological, social, or logistical barrier that the principal investigators feel&#xD;
             would preclude completion of the study protocol.&#xD;
&#xD;
          -  Plan for use of any anti-myeloma treatment other than melphalan (the use of total body&#xD;
             irradiation will NOT&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan Vogl</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson CC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abramson Cancer Center of the Unviersity of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 5, 2013</study_first_submitted>
  <study_first_submitted_qc>March 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2013</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

